Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study

Covid19 Clinical Trial

— COVID  

Official title:

Performance Assessment of SARS-CoV-2 Detection Through Analysis of Exhaled Breath Aerosols

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04508556
• Other study ID #: SARS-CoV-2 study
• Status: Completed
• Start date: September 30, 2020
• Est. completion date: December 19, 2020

Study information

• Verified date: September 2020
• Source: Owlstone Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary aim of this study is to investigate the performance of Breath Biopsy RD for the detection of SARS-CoV-2 in both a clinical and at home setting.

Description:

This study aims to evaluate Owlstone Medical's Breath Biopsy RD Collectors for the detection of SARS-CoV-2 infection. These single use disposable breath capture devices can be used independently by individuals and shipped to be analysed in a central lab for the presence of SARS-CoV-2 using established existing PCR assays available in any reference lab. The aerosol collectors furthermore directly sample exhaled breath aerosols. As such they directly sample the primary transmission route for the virus. This could result in a higher rate of retrieval of viral RNA in infected individuals thereby increasing the sensitivity of the applied PCR assay. This is underpinned by the fact that CT abnormalities in the lower airways appear to occur prior to upper respiratory tract samples becoming positive in cases suffering from nCOVID19, suggesting lower airway viral loads could be higher. Combined, this could enable more widespread access to diagnostics, reduce the need for repeat testing, decrease the need for healthcare professionals to perform diagnostic tests and reduce cross-contamination risk.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 19, 2020
• Est. primary completion date: December 19, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any adult >18 years with either a confirmed (phase 1) or suspected (phase 2&3) SARS-CoV-2 infection will be eligible to participate in this study.

Exclusion Criteria:

• Subject who are deemed unlikely to be able to maintain oxygen saturation of greater than 90% while breathing room air for 30 seconds

• Subject who require non-invasive ventilation or high flow nasal oxygen

• Subject who require inotropic medication to maintain adequate organ perfusion

• Subject who have a communication barrier and / or unable to comply with the instructions to use the Breath Biopsy test

Related Conditions & MeSH terms

• Covid19

Intervention

Device:
• Breath Biopsy face masks with removable filters and fitted PVA strip
Device developed for collection of breath samples

Diagnostic Test:
• Nasopharyngeal swab
Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
• oropharyngeal swabs
Is a method for collecting a clinical test sample from the back of the throat.

Locations

Country	Name	City	State
Netherlands	OLVG	Amsterdam

Sponsors (3)

Lead Sponsor	Collaborator
Owlstone Ltd	Maastricht University, OLVG

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluation of at home test	The aim of the final outcome is to evaluate the performance and acceptability of using the Breath Biopsy RD as an at home test for identification of the presence of SARS-CoV-2. The OLVG phone application used for triage of the presence of nCOVID-19 will be used to identify subjects at the highest risk of having nCOVID-19. These subjects will be sent a Breath Biopsy RD collector and oropharyngeal swab for at home testing. Any subject who has a positive Breath Biopsy test for SARS-CoV-2 will be contacted and advised to receive a nasopharyngeal test for assessment of viral presence. Both tests will be self-administered to mimic an at home use scenario. The performance of both tests will be confirmed from the perspective of 1. Adherence 2. Subject comfort 3. Number of SARS-CoV-2 positive cases.	1 year
Primary	Positive control for technical validation	The purpose of this stage is to confirm the optimal extraction protocol to detect the presence of SARS-CoV-2 from the aerosols captured in the Breath Biopsy RD device. Up to two Breath Biopsy RD sample will be collected alongside a nasopharyngeal. The swab obtained during this stage is to be analysed in parallel to the extracted breath aerosols in the lab of the lab and will be used as a positive control.	1 year
Secondary	Evaluation of test performance	The aim is to assess the test performance of the Breath Biopsy RD devices in a real live clinical setting. Subjects with a high clinical suspicion of nCOVID-19 based on clinical triage will be requested to participate. A single Breath Biopsy RD collector will be collected in parallel with the standard diagnostic work-up consisting of a CT-scan and a nasopharyngeal swab.	1 year